Sinocare

Sinocare EBITDA per Employee

The EBITDA per Employee of Sinocare (300298.SZ) as of Oct 21, 2026 is 25,727.90 CNY. In the previous year, EBITDA per Employee was 138,621.33 CNY — a change of -81.44% (lower).

EBITDA per Employee

25,727.90CNY

YoY

-81.44%

Last updated:

EBITDA per Employee of Sinocare is 2025 25,727.90 CNY. EBITDA per Employee of Sinocare was 2024 138,621.33 CNY. It decreases by -81.44% lower compared to the previous year.

The Sinocare EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
93,470.84 CNY
Jan 1, 2019
84,505.17 CNY
Jan 1, 2020
109,301.94 CNY
Jan 1, 2021
54,656.74 CNY
Jan 1, 2022
134,178.29 CNY
Jan 1, 2023
107,163.20 CNY
Jan 1, 2024
138,621.33 CNY
Jan 1, 2025
25,727.90 CNY
The Sinocare EBITDA per Employee history
YEAREBITDA per EmployeeYoY
25,727.90CNY-81.44%
138,621.33CNY+29.36%
107,163.20CNY-20.13%
134,178.29CNY+145.49%
54,656.74CNY-49.99%
109,301.94CNY+29.34%
84,505.17CNY-9.59%
93,470.84CNY+12.88%
82,807.68CNY+288.43%
21,318.72CNY-43.82%
37,946.47CNY-28.71%
53,229.90CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sinocare Stock analysis

What does Sinocare do? Sinocare, Inc. generates revenue through the development, production, and sale of chronic disease rapid detection products, primarily focusing on blood sugar monitoring systems. The company offers blood sugar testing instruments, related strips, blood sugar testing systems, and mobile blood sugar instruments under its SANNUO brand. These products are sold domestically and internationally, targeting healthcare providers and consumers managing diabetes. Sinocare also provides diabetes management information systems as part of its product portfolio. The SANNUO brand is central to Sinocare's sales strategy, with products distributed across domestic and overseas markets. The company's offerings include micro blood instant blood sugar monitoring systems, which are designed for chronic disease management. Sinocare's revenue streams are derived from direct sales of these medical devices and associated information systems to end-users and healthcare institutions. Sinocare's business model relies on the consistent demand for diabetes management solutions, with its SANNUO-branded products serving both individual consumers and healthcare facilities. The company's product range includes blood sugar testing instruments, strips, and mobile blood sugar instruments, all marketed under the SANNUO label. These products are distributed globally, supporting Sinocare's revenue generation through direct sales channels. Sinocare is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sinocare stock

EBITDA per Employee of Sinocare is 25,727.90 CNY in 2025.

EBITDA per Employee of Sinocare changed from 138,621.33 CNY to 25,727.90 CNY, representing a -81.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Sinocare since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Sinocare historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Sinocare

All Key Metrics — Sinocare